|3 Months Ended|
Mar. 31, 2018
|Notes to Financial Statements|
|NOTE 15 - CONCENTRATIONS||
Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and trade receivables. The Company places its cash and temporary cash investments with high credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit.
The Companys revenues earned from sale of products and services for the three months ended March 31, 2018 included 14%, 23% and 13% (aggregate of 50%) from three customers of the Companys total revenues.
The Company's revenues earned from sale of products and services for the three months ended March 31, 2017 included 12%, 15% and 16% (aggregate of 43%) from three customers of the Company's total revenues.
Four customers accounted for 13%, 25%, 11% and 28% (aggregate of 77%) of the Companys total accounts receivable at March 31, 2018 and three customers accounted for 12%, 19% and 13% (aggregate of 44%) of the Companys total accounts receivable at December 31, 2017.
The Company relies on Trinity Rx as its sole supplier of its Naltrexone implant.
The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.
Reference 1: http://www.xbrl.org/2003/role/presentationRef